Population-Based Human Papillomavirus Prevalence in Lampang and Songkla, Thailand
|
|
- Arline Harrington
- 6 years ago
- Views:
Transcription
1 MAJOR ARTICLE Population-Based Human Papillomavirus Prevalence in Lampang and Songkla, Thailand Sukhon Sukvirach, 1 Jennifer S. Smith, 6 Sirirat Tunsakul, 1 Nubia Muñoz, 6 Vitaya Kesararat, 2 Oranuj Opasatian, 3 Saibua Chichareon, 4 Vichien Kaenploy, 5 Rhoda Ashley, 8 Chris J. L. M. Meijer, 9 Peter J. F. Snijders, 9 Pierre Coursaget, 7 Silvia Franceschi, 6 and Rolando Herrero 6,10 1 Research Division, National Cancer Institute, Bangkok, 2 Lampang Hospital and 3 Provincial Health Office, Lampang, and 4 Prince of Songkla University and 5 Provincial Health Office, Songkla, Thailand; 6 International Agency for Research on Cancer, Lyon, and 7 Molecular Virology Laboratory, INSERM, Tours, France; 8 University of Washington, Seattle; 9 Vrije Universiteit Medical Center, Amsterdam, The Netherlands; 10 Proyecto Epidemiologico Guanacaste, San Jose, Costa Rica To investigate the prevalence and determinants of human papillomavirus (HPV) infection, the primary cause of cervical cancer, we studied 1741 women 15 years of age from Lampang and Songkla, Thailand. Exfoliated cervical cells were collected for Papanicolaou smear screening and DNA detection of 36 different HPV types. Serum immunoglobulin G antibodies against L1 virus-like particles (anti-vlps) of HPV-16, -18, -31, -33, and -58 were evaluated using enzyme-linked immunosorbent assay. Overall, 110 women (6.3%) were HPV DNA positive; the most common types were HPV-16, -52, and -72. The age-standardized prevalence of HPV DNA was higher among the 1035 women from Lampang (9.1%; 95% confidence interval [CI], ) than among the 706 women from Songkla (3.9%; 95% CI, 2.3% 5.6%). Anti-VLPs were found in 21.8% of all women and were more frequent among women from Lampang (29.2%) than among women from Songkla (10.9%). Major risk factors for cervical HPV DNA were age!35 years, HSV-2 seropositivity, and having a husband with extramarital sexual partners. Invasive cervical cancer (ICC) is the second most common cancer among women worldwide and the leading cancer in Thailand [1]. The estimated age-standardized incidence rate of ICC in Thailand is 20.7/100,000 population [1]. In 1993, 5500 new cases were reported, and the age-standardized incidence rates of ICC were highest in Chiang Mai (25.7/100,000) and Lampang Received 15 July 2002; accepted 10 December 2002; electronically published 26 March Presented in part: 19th International Papillomavirus Conference, Florianopolis, Brazil, 1 7 September 2001 (abstract P 43). Written informed consent was obtained from patients, and the study protocols were approved by the International Agency for Research on Cancer (IARC) Ethical Review Committee and the National Research Council in Thailand. Financial support: Ministry of Public Health and Cancer Research Foundation, National Cancer Institute, Thailand; Terry Fox Run Fund; IARC. Reprints or correspondence: Dr. Silvia Franceschi, International Agency for Research on Cancer, Unit of Field and Intervention Studies, 150 cours Albert Thomas, F Lyon Cedex 08, France (franceschi@iarc.fr). The Journal of Infectious Diseases 2003; 187: by the Infectious Diseases Society of America. All rights reserved /2003/ $15.00 (23.1/100,000), in the north, and lowest in Songkla (15.8/100,000), in the south [2]. Human papillomavirus (HPV) infection is the primary cause of ICC [3, 4]. Genital HPV infection is one of the most prevalent sexually transmitted infections worldwide, and the prevalence is consistently higher among women with higher-risk sexual behavior [5, 6]. More than 35 different HPV types may infect the female genital tract, and at least 14 HPV types are considered to be oncogenic or high-risk (HR) types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) [7]. To prevent HPV-associated cervical cancer in humans, candidate prophylactic HPV vaccines are being actively developed [8]. These vaccines are chiefly based on virus-like particles (VLPs) of HPV-16, alone or in conjunction with other HPV types. Vaccines against HPV-16 were shown to be safe and highly immunogenic [9] and efficacious in preventing persistent HPV- 16 infections [10]. Epidemiological data on the ageand type-specific prevalence of genital HPV infection 1246 JID 2003:187 (15 April) Sukvirach et al.
2 among women in different areas of the world are needed to define appropriate strategies for the introduction of an HPV vaccine. Little is currently known about the prevalence of HPV infection in population-based samples of women from areas throughout the world, particularly in Asia. In the framework of a multicenter study coordinated by the International Agency for Research on Cancer (IARC) of the prevalence of HPV infection in different countries worldwide, the National Cancer Institute in Bangkok, Thailand, performed 2 prevalence surveys of HPV infection and cervical intraepithelial neoplasia, in northern and in southern Thailand. We report the results of those studies here. SUBJECTS, MATERIALS, AND METHODS Study population and enrollment. A random sample of women who resided in the Koaka District, Lampang province, northern Thailand, was selected in each of eleven 5-year age groups: 15 19, 20 24, 25 29, 30 34, 35 39, 40 44, 45 49, 50 54, 55 59, 60 64, and 65 years. Complete population lists of all residents, obtained from community health centers, were used for this purpose. Of a total of 1893 selected women, 521 did not live at the address given on the population list or refused to participate. Eighty women were ineligible because they (1) were currently pregnant, (2) had a history of hysterectomy or conization, or (3) were mentally incompetent. A total of 1292 women (71.3% of eligible women) were, therefore, interviewed at home and then transported to Lampang Hospital between November 1997 and October Of these, 221 women (10 married and 211 single women) consented to provide a blood sample but refused to have a pelvic examination. The majority of the women who refused a pelvic examination were!25 years of age (83.7%) and reported being virgins (94.1%). Thus, 1071 women provided a cervical specimen for HPV DNA testing. In Songkla province, southern Thailand, sampling was restricted to women who had been married at some point, because of the large number of unmarried women who refused pelvic examination in Lampang. Women were chosen among residents from 3 districts: Ranod, Ratapoom, and Natawee. The type of population lists, age-stratified sampling methods, and exclusion criteria for participation in the study were the same as in Lampang. A total of 2288 women were randomly selected, but 1094 were not found at the address given on the population list or refused to join the study. An additional 197 women were ineligible due to exclusion criteria. Thus, 997 women (47.7% of eligible women) were interviewed and examined in 1 of 3 district clinics between September 1999 and June Seven women consented to provide a blood sample but refused to have a pelvic examination. Thus, 990 women provided a cervical specimen for HPV testing. At both sites, a standardized questionnaire on sociodemographic characteristics, sexual behavior, reproductive and contraceptive history, tobacco smoking and tobacco and betel chewing history, Papanicolaou smear screening history, and the woman s report of the sexual behavior of her husband was administered to study participants by trained female interviewers. Clinical examination and specimen collection. Participating women underwent a pelvic examination. Cervical exfoliated cells were collected for Pap smear screening and HPV DNA detection by sampling of the ectocervix with 2 wooden spatulas and the endocervix with a cytobrush (Cervibrush; CellPath). After Pap smear preparation, the remaining cervical cells were placed in tubes with PBS and stored in a cool box on ice. A 10-mL sample of blood was also collected from each consenting participant. All samples were shipped daily to central laboratories at the Lampang Hospital in Lampang and at the Songklanakarind Hospital in Songkla for processing. Exfoliated cervical cell specimens were processed by centrifugation at high speed (maximum, 3000 g) for 10 min. Excess PBS was discarded using a Pasteur pipette, and the remaining cell pellet was left in a small quantity of PBS ( ml), resuspended in the same volume of PBS, and shaken. The diluted cell pellet was then poured into 2 tubes, using a Pasteur pipette, and frozen at 80 C. Blood samples were centrifuged at 1500 g; aliquoted into plasma, buffy coats, and red blood cells; and stored at 20 C. All samples were sent on dry ice to the IARC (Lyon, France) for storage. All Pap smears from Lampang and Songkla were read at a central laboratory in the National Cancer Institute in Bangkok. Cytological smears were classified according to the Bethesda system. Participants with abnormal cytological findings were asked to undergo a colposcopic examination for biopsy and treatment, as appropriate. HPV DNA testing. HPV DNA testing was performed on exfoliated cervical cell samples in the pathology laboratory of Vrije University, Amsterdam. To analyze the quality of target DNA, b-globin gene-specific primers were used, and only b- globin positive samples were included in analyses. In Lampang, 35 (3.3%) of 1071 samples were b-globin negative, and 1 woman had no result of cytological examination, leaving a total of 1035 women with adequate HPV DNA and cytological findings. In Songkla, 272 (28%) of 990 samples were b-globin negative, and 12 women had no result of cytological examination, leaving a total of 706 women with adequate HPV DNA and cytological findings. HPV DNA positivity was assessed using a general primermediated GP5 /6 polymerase chain reaction (PCR). PCR positivity was assessed by hybridization of PCR products in an EIA using 2 HPV oligoprobe cocktails that together detect the following 36 HPV types: 6, 11, 16, 18, 26, 31, 33 35, 39, 40, 42 45, 51 59, 61, 66, 68, 70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to CP8304), 82 (IS39 and MM4 subtypes), HPV in Lampang and Songkla, Thailand JID 2003:187 (15 April) 1247
3 83 (equivalent to MM7), 84 (equivalent to MM8), and CP6108 [11]. Probes and procedures used for EIA detection are described elsewhere [11]. The sensitivity and specificity of EIA detection were previously determined using dilution lines of cloned HPVs or cervical smears in which these types were identified in earlier studies [12]. In addition, HPV positivity was assessed by low-stringency Southern blot analysis of PCR products with a cocktail probe of HPV-specific DNA fragments [13]. Subsequently, GP5 /6 PCR was repeated on positive samples in triplicate to generate sufficient products for further typing. After pooling these PCR products, typing was performed using EIA and HPV type specific oligoprobes for the HPV types listed above [14]. Samples that were GP5 /6 positive by lowstringency Southern blot analyses but could not be identified by EIA were considered to be uncharacterized HPV types. Special precautions were taken to minimize false-positive results of PCR, as has been described in detail elsewhere [13]. HPV types considered to be HR for this analysis included HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68. The group of low-risk (LR) types included all other HPV types tested. Some of the LR HPV types are not associated with cancer (e.g., HPV-6, -11, -40, -42, -43, and -44), whereas others have undetermined oncogenic potential (e.g., HPV-26, -34, -53, -54, -70, -72, and -73). Infection with 11 HPV type was considered to be HR if any HPV type detected was an HR type. HPV serological testing. Serological testing for the detection of antibodies against HPV VLPs was conducted using an ELISA, as described elsewhere [15]. In brief, HPV VLPs were produced in Sf21 insect cells using recombinant baculoviruses encoding the L1 gene of HPV-16, -18, -31, -33, and -58 [15 17] and were purified by isopyonic binding in cesium chloride. Flat-bottomed wells were coated overnight at 4 C with ng of VLPs (test well) or 200 ng of bovine serum albumin (BSA; control well) in PBS (ph 7.4). Each plasma sample was tested at a dilution of 1:10 against each of the 5 VLP types and BSA. The background reactivity in the BSA-coated wells was subtracted from the optical density in each of the HPV VLP coated wells. Negative values were adjusted to 0. The cutoff values for positivity were set at 0.4. For comparison with data on HPV DNA prevalence, data on the prevalence of anti-vlps against HPV-16, -18, -31, -33, and -58 are presented for 1033 women from Lampang and 706 women from Songkla who had valid HPV DNA and Pap smear results. Serological testing for herpes simplex virus type 2 (HSV- 2). Serological testing that was type specific for HSV-2 antibodies was conducted blindly in the virology laboratory of Children s Hospital and Regional Medical Center, Seattle, using an HSV-2 ELISA developed by Focus Technology [18]. HSV-2 positivity was confirmed by retesting of positive serum samples with another Focus Technology HSV-2 ELISA. Statistical analysis. The age-standardized prevalence of HPV DNA detection was computed using, as a standard, the population of Thailand in 1993 [2] or the world standard population [1]. Odds ratios (ORs) for HPV DNA detection and corresponding 95% confidence intervals (CIs) were calculated by means of unconditional multiple logistic regression, adjusted for place of residence and age (categorized into 6 groups:!25, 25 34, 35 44, 45 54, 55 64, and 65 years of age). Because of the similarity in the distribution of age, education, and sexual behavior variables and in the association with various risk factors for HPV DNA in Lampang and Songkla, data from the 2 sites were combined. Analyses were performed on data from 1741 women, including 14 women who reported themselves to be virgins. The statistical significance of trends for ORs was assessed by considering the categorical variable to be a continuous variable in the logistic model. In the final multivariate model, all variables that showed statistically significant (P!.05) associations with HPV DNA detection in the age- and center-adjusted analyses were included. RESULTS HPV prevalence and type-specific distribution. Overall, 6.3% of women were HPV DNA positive (table 1), and 28 different HPV types were detected. The majority of the HPVpositive women had infections with HR types (69.1%). HPV infections with multiple types were found in 1.7% of women (26.4% of HPV-positive women). When the presence of an HPV type in either a single or multiple infection was considered, the 3 most common types were 72, 52, and 16, each of which was found in 15 women (0.9% of all women and 13.6% of HPV-positive women). HPV-11, -33, -34, -35, -40, -43, -45, -66, -68, -MM7, -MM8, -CP6108, and -CP8061 were found only in women with multiple infections. The HPV prevalence was higher among 13 women with a diagnosis of low-grade squamous intraepithelial lesion (LSIL; 61.5%) and 11 women with high-grade squamous intraepithelial lesions (HSIL) or ICC (100%) than among 1673 women with normal cytological findings (4.8%). The HPV prevalence was 25.0% among women with cytological abnormalities that were not histologically confirmed. Among women with either LSIL or HSIL/ICC, HPV-52 was the most common type (found in 3 women with LSIL and 4 with HSIL/ICC). Among 80 women with normal cytological findings who were HPV DNA positive, the most common types found in either single or multiple infections were HPV-72, -16, -70, and -33. Age-specific prevalence of HPV infection. As shown in table 2, HPV DNA positivity overall was highest among women!35 years of age (9.8%) and then formed a plateau among 1248 JID 2003:187 (15 April) Sukvirach et al.
4 Table 1. Prevalence of type-specific human papillomavirus (HPV) infection of the cervix among 1741 women in Lampang and Songkla, Thailand. Variable Total population, no. (%) Women with abnormal cytology, no. (%) No histological confirmation a LSIL b HSIL/ICC c Women with normal cytology, no. (%) HPV DNA negative 1631 (93.7) 33 (75.0) 5 (38.5) 0 (0) 1593 (95.2) HPV DNA positive 110 (6.3) 11 (25.0) 8 (61.5) 11 (100) 80 (4.8) High risk type 76 (4.4) 9 (20.5) 7 (53.8) 11 (100) 49 (2.9) Low risk type 33 (1.9) 2 (4.5) 1 (7.7) 0 (0) 30 (1.8) 16 9 (0.52) (0.48) 18 7 (0.40) (0.24) 31 4 (0.23) d 2 (0.12) 39 4 (0.23) (0.18) 42 3 (0.17) (0.18) 44 1 (0.06) (0.06) 51 5 (0.29) (0.24) (0.69) (0.18) 54 1 (0.06) (0) 56 5 (0.29) (0.24) 58 3 (0.17) (0.12) 59 1 (0.06) (0.06) 70 7 (0.40) (0.36) (0.75) (0.78) CP (0.29) (0.30) X e 1 (0.06) (0.06) Single-type subtotal 81 (4.7) (3.6) 11, 33, 39, 66 1 (0.06) (0) 16, 31 1 (0.06) (0) 16, 18, 31, 35 1 (0.06) (0.06) 16, 33, 35 1 (0.06) (0.06) 16, 33, 42, 58 1 (0.06) d 0(0) 16, 34, 68 1 (0.06) (0.06) 16, 52 1 (0.06) (0.06) 18, 31 1 (0.06) (0.06) 18, 58 1 (0.06) (0.06) 31, 35 1 (0.06) (0) 31, 33, 39 1 (0.06) (0.06) 33, 35 3 (0.17) (0.12) 33, 58 4 (0.23) (0.18) 33, 58, 72 1 (0.06) (0.06) 33, 58, CP6108, CP (0.06) (0) 33, 70 1 (0.06) (0.06) 34, 68 1 (0.06) (0.06) 39, 68 1 (0.06) (0.06) 39, 52 1 (0.06) (0) 40, MM8, CP (0.06) (0.06) 43, 45 1 (0.06) (0.06) 52, 70 1 (0.06) (0.06) 72, CP (0.06) (0.06) MM7, MM8, CP (0.06) (0) Multiple-type subtotal 29 (1.7) (1.2) Total NOTE. High-risk HPV types are shown in bold. ASCUS, atypical squamous cells of undetermined significance; AGUS, atypical glandular cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; ICC, invasive cervical cancer; LSIL, low-grade squamous intraepithelial lesion. a Includes 20 women with ASCUS, 10 with AGUS, and 14 with abnormal cytology and normal histological findings. b Includes histological confirmation in 8 women with CIN grade I. c Includes 4 women with CIN grade II, 3 with CIN grade III, and 2 with ICC. d Includes 1 woman with ICC. e Uncharacterized type; not classified as low or high risk.
5 Table 2. Sociodemographic characteristics, chewing betel or tobacco, and smoking tobacco as risk factors for cervical human papillomavirus (HPV) infection in a population-based sample of women in Lampang and Songkla, Thailand. Variable HPV infection status Uninfected, no. Infected, no. (%) OR a (95% CI) Center Songkla (3.8) 1 b Lampang (8.0) 2.1 ( ) Age, years! (10.6) 2.5 ( ) (9.2) 2.1 ( ) (5.0) 1.1 ( ) (6.0) 1.4 ( ) (4.5) 1.0 ( ) (4.5) 1 b P for trend.001 Religion Buddhist (6.6) 1 b Muslim (1.0) 0.2 ( ) Christian 8 1 (11.1) 2.1 (0.2 18) Education None or some primary (3.6) 1 b Completed primary (6.2) 1.6 ( ) Secondary or higher (8.9) 2.0 ( ) P for trend.097 Marital status Married (6.7) 1 b Divorced 74 5 (6.3) 0.9 ( ) Widowed (4.7) 0.9 ( ) Single 15 0 (0) 0.0 Chewing betel or tobacco Never (6.9) 1 b Ever (3.2) 0.8 ( ) Smoking Never (7.0) 1 b Ever (3.5) 0.4 ( ) NOTE. CI, confidence interval; OR, odds ratio. a Adjusted for age and center. b Reference category. women 35 years of age (4.5% 6.0%). The prevalence of HR HPV types increased from 5.6% among women!25 years of age to 6.5% among those aged years and then gradually decreased with age to 2.9% among those aged 65 years (figure 1). For LR types, the highest prevalence was found among women!25 years of age (5.1%) and the lowest among women aged years (0.3%). Among HPV-positive women, the proportion of LR HPV infection was highest among women!25 years of age (48%). The majority of HPV-positive women had single-type infections in all age groups (data not shown). Figure 2 shows a comparison of the age-specific prevalence of HPV DNA of any type and the prevalence of DNA of and anti-vlps against HPV-16, -18, -31, -33, and -58 among study participants. Seropositivity for anti-vlps was 17.2% among women!25 years of age, increased to 26.9% among women years of age, and decreased thereafter. The age curves for HPV DNA of the same types as anti-vlps were notably lower than the anti-vlp age curves. The prevalence of anti- VLPs against 5 HPV types was higher in Lampang (29.2%) than in Songkla (10.9%) (data not shown). Risk factors for HPV infection. The prevalence of cervical HPV DNA was significantly higher in Lampang (8.0%; 95% CI, 6.4% 9.8%) than in Songkla (3.8%; 95% CI, 2.5% 5.5%) (table 2). Using the Thailand population in 1993 [2] as the standard, the age-standardized HPV prevalence was found to be 9.1% (95% CI, 7.1% 11.1%) in Lampang and 3.9% (95% CI, 2.3% 5.6%) in Songkla, respectively (prevalences were 9.1% and 3.7%, respectively, using the world standard population). The prevalence of HR HPV types was higher in Lampang (5.8%) than in Songkla (2.3%) ( P!.001), but the prevalence of LR types was similar (2.1% in Lampang and 1.6% in Songkla). Abnormal cytological findings were more common among women from Lampang (4.9%) than among those from Songkla (2.4%) ( P p.008; data not shown). HPV DNA detection was not statistically significantly associated with religion or marital status, but it was marginally more frequent among the most educated women. No association was found with chewing betel or tobacco, but women who reported a history of tobacco smoking (19.8%) appeared to have a lower risk of HPV DNA detection than did women who did not smoke (table 2). HPV positivity was not related to a younger age at menarche, first marriage, or intercourse (table 3). Most women (85.0%) reported having only 1 sexual partner in their lifetimes. Women who reported having 2 sexual partners in their lifetimes appeared to be at an increased risk of HPV DNA detection, but the risk trend was of borderline statistical significance. No HPV infection was detected among 14 women who reported being virgins. HPV DNA was significantly associated with a reported history of sexually transmitted infections (OR, 3.2) and HSV- 2 seropositivity (OR, 2.1). HPV DNA detection was also higher among women who reported that their husband had other sexual partners (OR, 1.9) or contact with prostitutes (OR, 1.6) (table 3). HPV DNA detection was not significantly associated with reproductive characteristics, including age at first pregnancy, number of pregnancies, and parity (table 4). Women who reported a history of abortion were at an increased risk (OR, 1.7). Use of contraceptives was unrelated to HPV detection, with the exception of condom use (OR, 2.0). Women who reported condom use, however, were significantly younger and more likely to be HSV-2 seropositive than were women who did not use condoms ( P!.01). The association between HPV DNA detection and living in 1250 JID 2003:187 (15 April) Sukvirach et al.
6 Figure 1. Type distribution of human papillomavirus infection in population-based samples of women from Lampang and Songkla, Thailand. Lampang, rather than Songkla, remained significant in the multivariate model (table 5). Independent risk factors for HPV infection included a woman s tobacco smoking history, HSV- 2 seropositivity, and report that the woman s husband had had other sexual partners. Associations with factors such as history of abortions, lifetime number of sexual partners, and history of condom use were attenuated and became nonsignificant in the final model. Risk factors for HPV infection did not appear to significantly differ between HR and LR HPV types, although infection with LR types appeared to be more strongly associated with HSV-2 seropositivity than did infection with HR types. The multivariate analyses presented in table 5 were repeated separately for women living in Lampang and those living in Songkla, and risk factors were consistent (data not shown). When women!35 years of age were compared with those 35 years of age, risk factors also were generally similar, although the association with having 2 sexual partners in a lifetime appeared to be stronger among younger women (OR, 2.2; 95% CI, ) than among older women (OR, 1.1; 95% CI, ). [19], although our sample size was too limited for reliable investigation of the type distribution of HPV infection among women with HSIL or ICC. The population-based prevalences of HPV-16 and -18 DNA types among women in our study were 0.9% (13.6% of HPV-positive women) and 0.6% (9.1% of HPV-positive women), respectively. Only a few studies using highly sensitive assays for HPV DNA detection have been conducted in less-developed countries [5, 19, 20, 23 30]. The overall HPV DNA prevalence of 6.3% (4.8% in women with normal cytological findings) in our study is among the lowest reported in the literature to date. It is similar to the prevalence seen in a control group of middleaged women in a case-control study of ICC in Spain (4.9%) [24]; among women with normal cytological findings in 4 studies in Bangkok, where HPV positivity ranged from 5% to 9% [27 30]; and among women with normal cytological findings in a study in Japan (4.5%) [31]. It is lower than the prevalences found among women with normal cytological findings in Costa Rica (11%) [19] and Mexico (14.5%) [5] and among women in the control group (mean age, 43 years) of a case-control study of ICC in Taiwan (9.2%) [25]. The prevalence of HPV DNA positivity that we found in Songkla (3.8%) is lower than the prevalence of 15.7% that was seen among middle-aged women in the control group of a hospital-based case-control study carried out by the IARC in the same province in Thailand [20]. The higher number of sexual partners and fewer refusals among control women in that case-control study [20], compared with the present study, may account for this discrepancy. A highly sensitive PCR-based assay was used in this study to detect a wide range of different HPV types, reducing the likelihood that HPV DNA positivity was underdetected. The specificity of our findings also appears to be high; none of the 14 women who reported themselves to be virgins were HPV DNA positive. Twenty-eight different HPV types were found in women in this study, which confirms that there is great DISCUSSION The age-standardized prevalence of cervical HPV DNA was 2- fold higher in population-based samples of women from Lampang (9.1%) than among women from Songkla (3.9%). When samples from the 2 centers were combined, the HPV DNA prevalence was 6.3%. HPV-52, -72, and -16 were the 3 most common types found by HPV DNA detection for the entire sample of women surveyed, whereas HPV-72, -16, and -70 were the most common types among women with normal cytological findings. HPV-52 was the most common type among the 68 women with abnormal cytological findings (14.7%), which may indicate that HPV-52 is of greater importance in cervical neoplasia in Thailand than elsewhere [7, 19 22]. As expected, our results confirm that the prevalence of HPV positivity increases with increasing severity of cervical neoplasia Figure 2. Prevalence of antibodies against virus-like particles (anti- VLPs) of human papillomavirus (HPV) types 16, 18, 31, 33, and 58 and HPV DNA of these 5 HPV types and of all types. HPV in Lampang and Songkla, Thailand JID 2003:187 (15 April) 1251
7 Table 3. Age and menarche and sexual behavior as risk factors for cervical human papillomavirus (HPV) infection in a populationbased sample of women in Lampang and Songkla, Thailand. Variable HPV infection status Uninfected, no. Infected, no. (%) OR a (95% CI) Age at menarche, years (8.1) 1 b (6.5) 0.9 ( ) (5.1) 0.8 ( ) P for trend.54 Age at first marriage, years (6.3) 1 b (6.9) 1.1 ( ) (6.8) 1.0 ( )! (5.4) 0.7 ( ) P for trend.23 Age at first intercourse, years (6.7) 1 b (6.5) 1.0 ( ) (6.7) 0.9 ( )! (5.6) 0.7 ( ) P for trend.21 Lifetime no. of sexual partners (0) (6.0) 1 b (9.0) 1.7 ( ) (8.9) 1.6 ( ) P for trend.07 Reported history of sexually transmitted infections Never (6.0) 1 b Ever (14.6) 3.2 ( ) Herpes simplex virus 2 serostatus Negative (4.8) 1 b Positive (10.1) 2.1 ( ) Husband has extramarital affairs No (4.9) 1 b Yes (9.0) 1.9 ( ) Husband frequents prostitute(s) No (5.4) 1 b Yes (9.0) 1.6 ( ) NOTE. CI, confidence interval; OR, odds ratio. a Adjusted for age and center. b Reference category. variability in the range of HPV types detected in exfoliated cervical cells at a population level [19]. HPV DNA positivity was highest among women!25 years of age, which is consistent with the high frequency with which HPV infection occurs when women start having sexual intercourse [5, 19]. The representativeness of our estimate of HPV DNA prevalence among women!25 years of age is limited, however, because young single women in Thailand generally were not willing to undergo a pelvic examination. A few studies have suggested that HPV prevalence may vary with age in a U-shaped fashion [5, 19]. In Costa Rica, the second peak of HPV DNA detection in women 165 years of age appeared to result from an increase in the prevalence of LR, rather than HR, HPV types [19]. In Mexico, a second peak among women 145 years of age appears to have resulted from an increase in both LR and HR HPV types. Our data from Thailand show no clear increase in the prevalence of HPV DNA detection among older women. Differences in HPV DNA prevalence found in different studies, overall and by age, may be partly accounted for by differences in cohort effects and PCR methods used for HPV detection (i.e., whether MY09/11, GP5 /6, or PGM09/ 11 primers are used). Results on risk factors for HPV infection in women provide further supportive evidence of the importance of the male role in HPV transmission to female partners [32, 33] in this Thai population, in which the vast majority (85.0%) of married women reported having only 1 sexual partner in their lifetimes. HPV infection was also positively correlated with HSV-2 seropositivity in women, which is considered to be a reliable marker for the woman s sexual behavior [34], as well as that of her male partner [35]. That the prevalence of HPV infection in Lampang was higher than that in Songkla does not appear to be explained by differences in sexual habits or in HPV testing methods. All samples were analyzed in parallel at a centralized laboratory. That the prevalence of anti-vlps against 5 HPV types was 3-fold higher among women from Lampang (29.2%) than among women from Songkla (10.9%) is consistent with HPV DNA findings and suggests that HPV infection varies between the 2 provinces. It is a source of concern, however, that the proportion of refusals to participate to our survey was higher in Songkla than in Lampang. That the prevalence of HPV infection was lower among women with a history of smoking tobacco than among women who had never smoked must be interpreted with caution, because the prevalence of smoking among women in Thailand is low. Although smoking has been consistently associated with an increased risk of ICC [20, 36], the influence of smoking on HPV infection is unclear; some studies have found an increased risk of HPV infection [37], no difference [5], or a reduced risk [33, 38 41] among smokers. Potential limitations of our study include that the survey, most notably in Songkla, had a relatively low participation rate. Because Pap smear screening is not widespread in Thailand, it is not, perhaps, surprising that a substantial proportion of women refused to participate in the study. The elevated prevalence of b-globin negativity among the exfoliated cervical cell samples, notably in Songkla, is another limitation and may be the result of problems in the transport of samples from rural areas to the Songklanakarind Hospital. Our results also showed 1252 JID 2003:187 (15 April) Sukvirach et al.
8 Table 4. Reproductive characteristics and contraceptive use as risk factors for cervical human papillomavirus (HPV) infection in a populationbased sample of women in Lampang and Songkla, Thailand. Variable HPV infection status Uninfected, no. Infected, no. (%) OR a (95% CI) Age at first pregnancy, years (6.7) 1 b (6.3) 0.9 ( )! (6.7) 0.8 ( ) P for trend.55 No. of pregnancies None 75 1 (1.3) 0.1 ( ) (9.1) 1 b (5.0) 0.8 ( ) (4.5) 0.8 ( ) P for trend.45 Parity None 90 1 (1.1) 0.1 ( ) (8.5) 1 b (4.9) 0.9 ( ) (4.4) 0.8 ( ) P for trend.18 Abortion Spontaneous Never (6.1) 1 b Ever (7.4) 1.5 ( ) Induced Never (6.1) 1 b Ever 85 9 (9.6) 1.5 ( ) Any Never (5.8) 1 b Ever (8.2) 1.7 ( ) Contraceptive use Oral Never (4.9) 1 b In past only (7.6) 1.1 ( ) 4 years current use (9.1) 1.1 ( ) 14 years current use 80 7 (8.1) 1.2 ( ) P for trend.66 Injectable or implant Never (5.5) 1 b In past only (6.4) 0.8 ( ) 4 years current use (11.5) 1.4 ( ) 14 years current use 45 4 (8.2) 1.1 ( ) P for trend.50 Condoms Never (6.0) 1 b Ever (10.8) 2.0 ( ) Intrauterine device Never (6.7) 1 b Ever (4.1) 0.6 ( ) NOTE. CI, confidence interval; OR, odds ratio. a Adjusted for age and center. b Reference category.
9 Table 5. Results of multivariate analysis of risk factors for cervical human papillomavirus (HPV) infection in a population-based sample of women in Lampang and Songkla, Thailand. Variable HPV type, OR a (95% CI) High risk Low risk Any Center Songkla 1 b 1 b 1 b Lampang 3.0 ( ) 1.6 ( ) 2.5 ( ) Age, years! ( ) 2.1 ( ) 1.6 ( ) ( ) 0.8 ( ) 1.2 ( ) ( ) 0.08 ( ) 0.6 ( ) ( ) 0.5 ( ) 0.9 ( ) ( ) 0.6 ( ) 0.8 ( ) 65 1 b 1 b 1 b Smoking Never 1 b 1 b 1 b Ever 0.5 ( ) 0.2 ( ) 0.4 ( ) Lifetime no. of sexual partners 1 1 b 1 b 1 b ( ) 1.8 ( ) 1.4 ( ) Herpes simplex virus 2 serostatus Negative 1 b 1 b 1 b Positive 1.4 ( ) 3.6 ( ) 1.9 ( ) Husband has extramarital affairs No 1 b 1 b 1 b Yes 1.5 ( ) 1.7 ( ) 1.5 ( ) History of abortion Never 1 b 1 b 1 b Ever 1.4 ( ) 1.9 ( ) 1.5 ( ) Condom use No 1 b 1 b 1 b Yes 1.3 ( ) 2.6 ( ) 1.6 ( ) NOTE. CI, confidence interval; OR, odds ratio. a Adjusted for all variables in the table other than the current category. b Reference category. a relatively low prevalence of LSIL and HSIL among women screened in our study, pointing to some potential underdetection of cervical abnormalities. This should not bias, however, the overall detection of HPV DNA in participating women. Because of the relatively low number of HPV-positive women in our study, statistical power to detect meaningful differences in the risk factors for HR and LR HPV types that have been found in some other studies [38, 42] was also limited. In conclusion, the prevalence of HPV infection was relatively low in population-based samples of women from Lampang and Songkla, Thailand, which suggests that the spread of HPV infection in the country is relatively limited. Because the vast majority of the women surveyed reported having only 1 sexual partner in their lifetimes, the sexual behavior of a woman s husband in Thailand appears to be an important determinant of a woman s HPV infection status. That the prevalence of HPV DNA and anti-vlps was higher among women from Lampang than among women from Songkla is consistent with a 50% difference seen in the incidence of ICC between the 2 provinces. Acknowledgments We acknowledge the collaboration of Sujin Wongchusri (Lampang Hospital, Lampang, Thailand), Pipat Yingseri and Boonterm Tunsurat (Lampang Provincial Health Office, Lampang), Sutep Watcharapiyanan (Songkla Provincial Health Office, Songkla, Thailand), Wisit Tunnukij and Apichai Deechaisate (Somdej Hospital, Natawee, Songkla), Teerawat Kornsilp 1254 JID 2003:187 (15 April) Sukvirach et al.
10 (Ranod Hospital, Songkla), and Suwit Kongchuchuy (Ratapoom Hospital, Songkla) and thank them for providing local management and advice. We thank Manop Lertsakornsiri, Busabun Preda-ananthasook, Suwit Pichayanan, and Supavan Hongpatarakeree (Lampang Hospital); Sudjid Kaewsuksri and Supanee Suwan (Ranod Hospital); Sudee Koll and Saniya Mugem (Ratapoom Hospital); and Wannee Janeruksukum and Yuwadee Tanbutr (Somdej Hospital), for conducting the gynecologic examinations and collecting the cervical specimens. We also thank Supanee Nimpoonsawad (Koa-ka Health Office, Lampang) and Sunanta Pongpaiboon (Songkla Provincial Health Office), for their supervision of the health care workers. All health care workers in Koa-ka, Ranod, Ratapoom, and Natawee who were responsible for inviting women in the sampling list to participate in this project are also recognized. We thank Ghanha Loeyont (Lampang Hospital) and Pa-op Kaewsuwan (Songklanakarind Hospital, Songkla), for processing the collected biological specimens; Pattarita Venunan and Nuanpun Anantawatanawong (National Cancer Institute, Bangkok, Thailand), for interpreting cytological specimens; Chantakarn Songsawang and Pattarita Venunan, for training gynecologic nurses; Mati Rienkijkarn and Punporn Srimanop (National Cancer Institute), for data management; Sineenart Sontipong (National Cancer Institute), for statistical advice; and Jolein Pleijster (Vrije Universiteit, Amsterdam) and Annie Arslan (International Agency for Research on Cancer, Lyon, France), for data analysis and helpful comments. References 1. Ferlay J, Parkin DM, Pisani P. GLOBOCAN. Vol 1. Cancer incidence and mortality worldwide. IARC Cancerbase no. 3 [CD-ROM]. Lyon, France: IARC Press, Deerasamee S, Martin N, Sontipong S, et al. Cancer in Thailand, vol. II, International Agency for Research on Cancer Technical Report no. 34. Lyon, France: IARC Press, International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 1995; Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: Lazcano-Ponce E, Herrero R, Muñoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91: Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000; 163: Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88: Schiller JT, Lowy DR. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001; 28: Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000; 87: Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5 /GP6 -mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: Walboomers JM, Melkert P, van den Brule AJ, Snijders PJ, Meijer CJ. The polymerase chain reaction for human papillomavirus screening in diagnostic cytopathology of the cervix. In: Herrington CS, McGee O, eds. Diagnostic molecular pathology: a practical approach. Oxford: Oxford University Press, 1992: Jacobs MV, de Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995; 33: Combita AL, Bravo MM, Touze A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 2002; 97: Touze A, de Sanjosé S, Coursaget P, et al. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 2001; 39: Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002; 76: Ribes JA, Hayes M, Smith A, Winters JL, Baker DJ. Comparative performance of herpes simplex virus type 2-specific serologic assays from Meridian Diagnostics and MRL Diagnostics. J Clin Microbiol 2001; 39: Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and all grades of cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92: Chichareon S, Herrero R, Muñoz N, et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 1998; 90: Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: Bhattarakosol P, Poonnaniti A, Niruthisard S. Detection and typing of human papillomavirus in cervical cancer in the Thai. J Med Assoc Thai 1996; 79:S Castellsagué X, Menendez C, Loscertales MP, et al. Human papillomavirus genotypes in rural Mozambique. Lancet 2001; 358: Muñoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996; 23: Liaw KL, Hsing AW, Chen CJ, et al. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer 1995; 62: Ferrera A, Velema JP, Figueroa M, et al. Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: a case-control study. Int J Cancer 1999; 82: Siritantikorn S, Laiwejpithaya S, Siripanyaphinyo U, et al. Detection and typing of human papilloma virus DNAs in normal cervix, intraepithelial neoplasia and cervical cancer in Bangkok. Southeast Asian J Trop Med Public Health 1997; 28: Lertworapreecha M, Bhattarakosol P, Niruthisard S. Detection and typing of human papillomavirus in cervical intraepithelial neoplasia grade III in Thai women. Southeast Asian J Trop Med Public Health 1998; 29: HPV in Lampang and Songkla, Thailand JID 2003:187 (15 April) 1255
11 29. Thomas DB, Ray RM, Koetsawang A, et al. Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. Am J Epidemiol 2001; 153: Sukvirach S, Pitakpraiwan P, Kosiyatrakul T, Hankittipongpaisarn P. Detection of human papillomavirus DNA in normal and cervical carcinoma tissues of Thai females. Thai Cancer J 1994; 20: Sasagawa T, Dong Y, Saijoh K, Satake S, Tateno M, Inoue M. Human papillomavirus infection and risk determinants for squamous intraepithelial lesion and cervical cancer in Japan. Jpn J Cancer Res 1997; 88: Bosch FX, Castellsagué X, Muñoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996; 88: Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996; 174: Cowan FM, Johnson AM, Ashley RL, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ 1994; 309: Smith JS, Herrero R, Muñoz N, et al. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis 2001; 28: Ngelangel C, Muñoz N, Bosch FX, et al. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst 1998; 90: Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000; 183: Kjaer SK, van den Brule AJ, Bock JE, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997; 6: Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis 1993; 20: Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of typespecific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169: Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: Franco EL, Villa LL, Ruiz A, Costa MC. Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J Infect Dis 1995; 172: JID 2003:187 (15 April) Sukvirach et al.
The Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationPopulation-Based Prevalence and Age Distribution of Human Papillomavirus Among Women in Santiago, Chile
Cancer Epidemiology, Biomarkers & Prevention 2271 Short Communication Population-Based Prevalence and Age Distribution of Human Papillomavirus Among Women in Santiago, Chile Catterina Ferreccio, 1 Rodrigo
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationEpidemiologic Profile of Type-Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica
MAJOR ARTICLE Epidemiologic Profile of Type-Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica Rolando Herrero, 1,a Philip E. Castle, 2,a Mark Schiffman, 2 M. Concepción
More informationHUMAN PAPILLOMAVIRUS INFECTION AND INVASIVE CERVICAL CANCER IN PARAGUAY
Int. J. Cancer: 85, 486 491 (2000) 2000 Wiley-Liss, Inc. Publication of the International Union Against Cancer HUMAN PAPILLOMAVIRUS INFECTION AND INVASIVE CERVICAL CANCER IN PARAGUAY Pedro A. ROLÓN 1,
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationDeterminants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 5 Printed in U.S.A. DOI: 10.1093/aje/kwg171 Determinants of Clearance
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationFREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION
Arch. Biol. Sci., Belgrade, 66 (4), 1653-1658, 2014 DOI:10.2298/ABS1404653M FREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION IN WOMEN IN MONTENEGRO GORDANA MIJOVIĆ 1, TATJANA JOVANOVIĆ
More informationARTICLES. Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention
ARTICLES Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention Xavier Castellsagué, Mireia Díaz, Silvia de Sanjosé, Nubia Muñoz,
More informationMaterials and Methods
8 A Prospective Study of Human Papillomavirus (HPV) Type 16 DNA Detection by Polymerase Chain Reaction and Its Association with Acquisition and Persistence of Other HPV Types Kai-Li Liaw, 1 Allan Hildesheim,
More informationDevelopment and Duration of Human Papillomavirus Lesions, after Initial Infection
MAJOR ARTICLE Development and Duration of Human Papillomavirus Lesions, after Initial Infection Rachel L. Winer, 1 Nancy B. Kiviat, 2 James P. Hughes, 3 Diane E. Adam, 1 Shu-Kuang Lee, 3 Jane M. Kuypers,
More information2. Studies of Cancer in Humans
346 IARC MONOGRAPHS VOLUME 72 2. Studies of Cancer in Humans 2.1 Breast cancer 2.1.1 Results of published studies Eight studies have been published on the relationship between the incidence of breast cancer
More informationConcurrent and Sequential Acquisition of Different Genital Human Papillomavirus Types
1097 Concurrent and Sequential Acquisition of Different Genital Human Papillomavirus Types Katherine K. Thomas, 1 James P. Hughes, 1 Jane M. Kuypers, 2 Nancy B. Kiviat, 2 Shu-Kuang Lee, 1 Diane E. Adam,
More informationHuman Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea
JOURNAL OF CANCER PREVENTION Vol. 21, No. 2, June 2016 http://crossmark.crossref.org/dialog/?doi=10.15430/jcp.2016.21.2.104&domain=pdf&date_stamp=2016-6-30 http://dx.doi.org/10.15430/jcp.2016.21.2.104
More informationSingle and multiple human papillomavirus infections in cervical abnormalities in Portuguese women
ORIGINAL ARTICLE VIROLOGY Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women A. Pista*, A. Oliveira*, N. Verdasca and F. Ribeiro National Laboratory of STI
More informationPromoting Cervical Screening Information for Health Professionals. Cervical Cancer
Promoting Cervical Screening Information for Health Professionals Cervical Cancer PapScreen Victoria Cancer Council Victoria 1 Rathdowne St Carlton VIC 3053 Telephone: (03) 635 5147 Fax: (03) 9635 5360
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationPapers. Abstract. Introduction. Methods
Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study Susanne
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationEarly Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young Women
Research Article Cancer Epidemiology, Biomarkers & Prevention Early Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young Women Rachel L. Winer 1, James
More informationPrevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign
Vu et al. BMC Cancer 2013, 13:53 RESEARCH ARTICLE Open Access Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign Lan TH Vu 1*, Dieu Bui 2 and Ha TT Le
More informationHuman Papillomaviruses and Cervical Cancer in Bangkok. I. Risk Factors for Invasive Cervical Carcinomas with Human Papillomavirus Types 16 and 18 DNA
American Journal of Epidemiology Copyright 2 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 5,. 8 Printed in U.S.A. Risk Factors for Cervical Cancers with
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationA systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions
British Journal of Cancer (2000) 83(5), 561 565 doi: 10.1054/ bjoc.2000.1375, available online at http://www.idealibrary.com on A systematic review of the role of human papilloma virus (HPV) testing within
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationA Population-Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women
MAJOR ARTICLE A Population-Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women Philip E. Castle, 1 Mark Schiffman, 1 M. Concepcion Bratti, 6 Allan Hildesheim, 1 Rolando Herrero,
More informationComparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis
British Journal of Cancer (2003) 89, 101 105 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Short Communication Comparison of HPV type distribution in high-grade cervical lesions and cervical
More informationType-Specific Incidence and Persistence of HPV Infection among Young Women: A Prospective Study in North India
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.3.1019 Type-Specific Incidence and Persistence of HPV Infection among Young Women in North India RESEARCH COMMUNICATION Type-Specific Incidence and Persistence
More informationA Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus
1574 Cancer Epidemiology, Biomarkers & Prevention A Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus Tammy S. Shields,
More informationHuman papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Human papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands Mitchell S Wachtel 1,
More informationPAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
More informationHPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions
British Journal of Cancer (2005) 92, 1388 1392 All rights reserved 0007 0920/05 $30.00 www.bjcancer.com HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile
More informationHuman papillomavirus infections among Japanese
Human papillomavirus infections among Japanese Blackwell Publishing Asia women: age-related prevalence and type-specific risk for cervical cancer Mamiko Onuki, 1 Koji Matsumoto, 1,4 Toyomi Satoh, 1 Akinori
More informationWhat is a Pap smear?
Pap smear What is a Pap smear? A Pap smear is a test that checks for changes in the cells of your cervix. The cervix is the lower part of the uterus that opens into the vagina. Developed over forty years
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEpidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
The new england journal of medicine original article Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer Nubia Muñoz, M.D., F. Xavier Bosch, M.D., Silvia de Sanjosé,
More informationHUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS
HUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS XIAO-WEI SUN, M.D., LOUISE KUHN, PH.D., TEDD V. ELLERBROCK, M.D., MARY ANN CHIASSON, DR.P.H., TIMOTHY J. BUSH, B.A.,
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationLow grade squamous intra-epithelial lesions and human papillomavirus infection in Colombian women
British Journal of Cancer (2002) 87, 1417 1421 All rights reserved 0007 0920/02 $25.00 www.bjcancer.com Low grade squamous intra-epithelial lesions and human papillomavirus infection in Colombian women
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationRESEARCH. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
Short term of human papillomavirus and risk of cervical precancer and cancer: population based cohort study Philip E Castle, investigator, 1 Ana Cecilia Rodríguez, medical epidemiologist, 3 Robert D Burk,
More informationHuman papillomavirus infection in Shanxi Province, People s Republic of China: a population-based study
British Journal of Cancer (2006) 95, 96 101 All rights reserved 0007 0920/06 $30.00 www.bjcancer.com Human papillomavirus infection in Shanxi Province, People s Republic of China: a population-based study
More informationPersistence of Genital Human Papillomavirus Infection in a Long-Term Follow-Up Study of Female University Students
MAJOR ARTICLE Persistence of Genital Human Papillomavirus Infection in a Long-Term Follow-Up Study of Female University Students Laura K. Sycuro, 1,4 Long Fu Xi, 1 James P. Hughes, 2 Qinghua Feng, 3 Rachel
More informationOpinion: Cervical cancer a vaccine preventable disease
Opinion: Cervical cancer a vaccine preventable disease Leon Snyman Principal specialist at the Department of Obstetrics and Gynaecology, Gynaecological Oncology unit, University of Pretoria and Kalafong
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationand treating joins with the top of canal). at risk for cervical carcinomas, cervix.
CERVICAL CANCER Worldwide, cervical cancer is twelfth most common and the fifth most deadly cancer in women. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year. Cervical
More informationEpidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women
Tang et al. Virology Journal (2017) 14:84 DOI 10.1186/s12985-017-0751-3 RESEARCH Open Access Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationClinical Performance of Roche COBAS 4800 HPV Test
JCM Accepts, published online ahead of print on 9 April 2014 J. Clin. Microbiol. doi:10.1128/jcm.00883-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 1 2 3 4 5 6 Clinical
More informationShrestha P CORRESPONDENCE
NJOG 2015 Jul-Dec; 20 (2):45-49 Original Article Shrestha P 1 2 2 1 Department of Obstetrics and Gynecology, Patan Academy of Health Science, Lalitpur, 2 Department of Obstetrics and Gynecology, Tribhuvan
More informationThe promise of HPV vaccines for Cervical (and other genital cancer) prevention
The promise of HPV vaccines for Cervical (and other genital cancer) prevention CONTROVERSIES IN OBSTETRICS GYNECOLOGY & INFERTILITY Barcelona March 27 F. Xavier Bosch Catalan Institute of Oncology CURRENT
More informationThe Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus Positive, Cytologically Normal Women Over a 10-Year Period
Published Online First on October 23, 2006 as 10.1158/0008-5472.CAN-06-1057 Research Article The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus Positive, Cytologically Normal
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationCervical Cancer Screening - Improving PAP Rates. Objectives
Cervical Cancer Screening - Improving PAP Rates Dineo Khabele, MD, FACOG, FACS Assistant Professor Division of Gynecologic Oncology Vanderbilt University Medical Center Objectives 1. Review the current
More informationBRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM
BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM DATE: NOVEMBER 19, 2016 PRESENTER: DR. DIRK VAN NIEKERK 1 Conflict of Interest Disclosure Nothing to disclose 2 ..in the beginning of the malady it
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationHPV vaccine perspectives Dr. David Prado Cohrs
HPV vaccine perspectives Dr. David Prado Cohrs Universidad Francisco Marroquín, Guatemala President of the Sexually Transmitted Diseases Committee, SLIPE Disclosure statement The presenter has received
More information2 HPV E1,E2,E4,E5,E6,E7 L1,L2 E6,E7 HPV HPV. Ciuffo Shope Jablonska HPV Zur Hausen HPV HPV16. HPV-genome.
58 2 pp.155-164 2008 2. HPV 20 HPV HPV HPV HPV HPV L1 HPV-DNA 16/18 2 HPV16 /18 6/11 4 2 100 1 Ciuffo 1907 20 Shope 1933 Raus 1934 20 70 Jablonska HPV Orth HPV5 8 1983 zur Hausen HPV16 1 HPV-genome 920-8641
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationTitle: Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women
Author's response to reviews Title: Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women Authors: Jia Ji (jackie.j.ji@gmail.com) He Wang (hewangpeking@gmail.com) Jennifer S. Smith
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationAbstract. Int J Gynecol Cancer 2006, 16,
Int J Gynecol Cancer 2006, 16, 1801 1808 The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan Cooperative Oncologic Group Study C.-A. CHEN*,
More informationThe new Cervical Screening Test for Australian women: Louise Farrell
The new Cervical Screening Test for Australian women: Louise Farrell Outline and explain the changes to the National Cervical Screening Program due to commence in Dec 2017 LEARNING OBJECTIVES FOR TODAY
More informationCONDOM USE PROMOTES REGRESSION OF CERVICAL INTRAEPITHELIAL NEOPLASIA AND CLEARANCE OF HUMAN PAPILLOMAVIRUS: A RANDOMIZED CLINICAL TRIAL
Int. J. Cancer: 107, 811 816 (2003) 2003 Wiley-Liss, Inc. Publication of the International Union Against Cancer CONDOM USE PROMOTES REGRESSION OF CERVICAL INTRAEPITHELIAL NEOPLASIA AND CLEARANCE OF HUMAN
More informationRole of paan chewing and dietary habits in cervical carcinoma in Chennai, India
British Journal of Cancer (2003) 88, 1388 1393 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Role of paan chewing and dietary habits in cervical carcinoma in Chennai, India T Rajkumar 1, S Franceschi*,2,
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationHe Said, She Said: HPV and the FDA. Audrey P Garrett, MD, MPH June 6, 2014
He Said, She Said: HPV and the FDA Audrey P Garrett, MD, MPH June 6, 2014 Disclosure Speaker for Merck Gardasil Speaker for Hologic Thin Prep and Cervista Cervical Cancer Screening: 21 st century Dr. Papanicolaou
More informationEffect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric casecontrol
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric casecontrol study Victor Moreno, F Xavier Bosch, Nubia Muñoz, Chris J L M Meijer,
More informationProfile Of Cervical Smears Cytology In Western Region Of Saudi Arabia
ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 1 Number 2 Profile Of Cervical Smears Cytology In Western Region Of Saudi Arabia I Mansoor Citation I Mansoor. Profile Of Cervical Smears
More informationINTRODUCTION HUMAN PAPILLOMAVIRUS
INTRODUCTION HUMAN PAPILLOMAVIRUS Professor Anna-Lise Williamson Institute of Infectious Disease and Molecular Medicine, University of Cape Town National Health Laboratory Service, Groote Schuur Hospital
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationHPV vaccination: the promise & problems
Review Article Indian J Med Res 130, September 2009, pp 322-326 vaccination: the promise & problems R. Sankaranarayanan Screening Group, International Agency for Research on Cancer, Lyon, France Received
More informationHuman Papillomavirus Genotypes and the Cumulative 2-Year Risk of Cervical Precancer
MAJOR ARTICLE Human Papillomavirus Genotypes and the Cumulative 2-Year Risk of Cervical Precancer Cosette M. Wheeler, 1,2 William C. Hunt, 1 Mark Schiffman, 3 and Philip E. Castle, 3 for the Atypical Squamous
More informationSilvia Franceschi Infections and Cancer Epidemiology Group International Agency for Research on Cancer Lyon, France
From epidemiology to cancerpreventing vaccines: the example of HPV Silvia Franceschi Infections and Cancer Epidemiology Group International Agency for Research on Cancer Lyon, France Milan, 19 March 2007
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationDetection of Human Papillomavirus DNA in Cytologically Normal Women and Subsequent Cervical Squamous Intraepithelial Lesions
Detection of Human Papillomavirus DNA in Cytologically Normal Women and Subsequent Cervical Squamous Intraepithelial Lesions Kai-Li Liaw, Andrew G. Glass, M. Michele Manos, Catherine E. Greer, David R.
More informationEpidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract
Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract Kevin Ault, Emory University Journal Title: Infectious Diseases in Obstetrics and Gynecology Volume: Volume
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More information- ii - Rights c
- ii - Rights c - iii - Preface Preface to the third edition Since the first edition of the HPV Information Centre, GLOBOCAN, one of the landmark products of the International Agency for Research on Cancer
More informationClinical Study Reducing the Health Burden of HPV Infection Through Vaccination
Infectious Diseases in Obstetrics and Gynecology Volume 2006, Article ID 83084, Pages 1 5 DOI 10.1155/IDOG/2006/83084 Clinical Study Reducing the Health Burden of HPV Infection Through Vaccination David
More informationDETERMINANTS OF HIGH-RISK HPV SEROPREVALENCE AND DNA PREVALENCE IN MID-ADULT WOMEN. Patricia Sadate-Ngatchou. A thesis
DETERMINANTS OF HIGH-RISK HPV SEROPREVALENCE AND DNA PREVALENCE IN MID-ADULT WOMEN Patricia Sadate-Ngatchou A thesis submitted in partial fulfillment of the requirements for the degree of Master of Public
More informationRisk factors for the acquisition of genital warts: are condoms protective?
312 Sex Transm Inf 1999;75:312 316 Original article Academic Unit of Sexual Health Medicine, Sydney Hospital, Sydney, Australia LMWen C S Estcourt A Mindel Department of Public Health and Community Medicine,
More informationPerformance of HPV Testing vs. Cytology for Cervical Cancer Screening in Senegal. Katherine McLean. A thesis submitted in partial fulfillment of the
Performance of HPV Testing vs. Cytology for Cervical Cancer Screening in Senegal Katherine McLean A thesis submitted in partial fulfillment of the requirements for the degree of Master of Public Health
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study Citation for published version: Cuschieri, K, Cubie, H,
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More informationCorrelation of HPV Types in Archived ASCUS Samples
Correlation of HPV Types in Archived ASCUS Samples Sharon Wah-Suet NG 1, Stephen Tsui-Hoi Lo 2, Daniel Chuen-Chu TAM 1 1 Genepath Technology Limited 2 Molecular Pathology Laboratory, Department of Pathology,
More informationReproductive Factors, Oral Contraceptive Use, and Human Papillomavirus Infection: Pooled Analysis of the IARC HPV Prevalence Surveys
2148 Reproductive Factors, Oral Contraceptive Use, and Human Papillomavirus Infection: Pooled Analysis of the IARC HPV Prevalence Surveys Salvatore Vaccarella, 1 Rolando Herrero, 2 Min Dai, 1 Peter J.F.
More informationCytomorphologic Features According to HPV DNA Type in Histologically Proven Cases of the Uterine Cervix
The Korean Journal of Pathology 2011; 45: 612-620 http://dx.doi.org/10.4132/koreanjpathol.2011.45.6.612 Cytomorphologic Features According to HPV DNA Type in Histologically Proven Cases of the Uterine
More informationPrevalence and determinants of high risk human papilloma virus in Hyderabad, India
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Chandana V et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):1012-1018 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180883
More informationHPV Epidemiology and Natural History
HPV Epidemiology and Natural History Rachel Winer, PhD, MPH Associate Professor Department of Epidemiology University of Washington School of Public Health rlw@uw.edu Human Papillomavirus (HPV) DNA virus
More informationFocus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010
HPV Vaccination: Science and Practice George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics Director, Colposcopy Clinic,
More informationAbstract Aim To evaluate the presence of high risk human papillomaviruses (HPV) in cervical smears showing intraepithelial neoplasia
J Clin Pathol 1999;52:17 22 17 Department of Gynaecology, Friedrich Schiller University, Bachstr 18, 07740 Jena, Germany I Nindl B Lotz U Endisch A Schneider Department of Pathology, Friedrich Schiller
More information